Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)

This study has been terminated.
(inadequate enrollment rate)
Sponsor:
Information provided by (Responsible Party):
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT01233635
First received: November 2, 2010
Last updated: January 4, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2007
  Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)